Gonorrhea Treatment Drugs Market Share

North America Market Statistics

On the basis of geographical analysis, the gonorrhea treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America industry is set to dominate majority revenue share by 2036, on the back of easy availability of advanced technology and high standards of healthcare infrastructure in the region. In addition, increasing awareness about the disease and promising reimbursement policies are also expected to drive market growth in the region.

APAC Market Analysis

However, the gonorrhea treatment market in Asia Pacific is assessed to witness the highest growth during the forecast period ascribing to the rising prevalence of the disease, rapid change in lifestyles and growing availability of cure for sexually transmitted diseases in the region. In India, more than 5% of the population is affected with a STD. On an average, every year 8-25% men suffer from gonorrhea.

Frequently Asked Questions (FAQ)

Increasing prevalence of gonorrhea globally and growing implementation of national screening programs are major growth drivers for the market.

The market is anticipated to attain a modest CAGR over the forecast period, i.e., 2021 â€“ 2029.

Negative perception about people visiting STD clinics is estimated to hamper the market growth.

Asia Pacific will provide more business opportunities in the future owing to the increasing prevalence of gonorrhea and rapidly changing lifestyles.

The major players in the market are Pfizer Inc., Allergan Inc., F. Hoffman-La Roche Ltd, GlaxoSmithKline plc., and others.

Gonorrhea Treatment Drugs Market Share